novo nordisk cuts prices for its glp-1 drugs. as Trump administration pushes cheaper GLP-1s Despite Novo Nordisk price cut,

Meanwhile, 57% cover the drugs for diabetes only, also up 8 percentage points from the prior year and 19% of those employers are also considering adding coverage for weight loss

doi: 10.1016/j.molmet.2022.101533, 50

Chen D, Li Q, Liang H, Huang L, Zhou H, Zheng X, et al

Whether GIP-based co-agonists can provide greater maximal clinical efficacy, relative to optimized GLP-1R agonists remains unknown, and may be further evaluated in Phase 3 studies

26 (27.1%) were symptomatic uncomplicated, and 32 (33.3%) were symptomatic complicated meanwhile, 38 (39.6%) were asymptomatic, as shown in Fig

They augment glucose-dependent insulin production while inhibiting glucagon, hence enhancing glycaemic control without the danger of hypoglycaemia (Meloni et al